Integrating antiangiogenic therapy for advanced urothelial carcinoma: Rationale for a phase ii study of gemcitabine, cisplatin, and sunitinib

Research output: Contribution to journalReview articlepeer-review

Fingerprint

Dive into the research topics of 'Integrating antiangiogenic therapy for advanced urothelial carcinoma: Rationale for a phase ii study of gemcitabine, cisplatin, and sunitinib'. Together they form a unique fingerprint.

Medicine & Life Sciences